Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial

被引：0
|
作者：
Aixin Shi
Panpan Xie
Lasse Lykke Nielsen
Trine Vang Skjøth
Xuemei He
Sine Pfeiffer Haugaard
机构：
[1] Chinese Academy of Medical Sciences,Clinical Trial Center, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine
[2] Novo Nordisk A/S,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Diabetes; Glucagon-like peptide-1 receptor agonist; Pharmacokinetics; Randomised controlled trial; Semaglutide; Steady state exposure;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：550 / 561
页数：11
相关论文
共 50 条
  • [21] Results from a randomized, double-blind, placebo-controlled, phase 1 trial evaluating sebetralstat pharmacokinetics, pharmacodynamics, and safety/tolerability in healthy Japanese, Chinese, and white adults
    Hide, M.
    Iverson, M.
    Jhee, S.
    Hansen, E.
    Duckworth, E. J.
    Hampton, S. L.
    Yoon, E.
    Honda, D.
    ALLERGY, 2023, 78 : 29 - 29
  • [22] First-in-human safety, tolerability, and pharmacokinetics of ammoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I study
    Shen, Qi
    Hu, Chao
    Miao, Jia
    Chen, Junxia
    Peng, Yueying
    Pan, Tingting
    He, Xiaolin
    Yuan, Jing
    Ni, Shaonan
    Wang, Yongsheng
    Luo, Zhu
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 159
  • [23] Safety, Tolerability, and Pharmacokinetics of β-Cryptoxanthin Supplementation in Healthy Women: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial
    Tan, Karen M. L.
    Chee, Jolene
    Lim, Kezlyn L. M.
    Ng, Maisie
    Gong, Min
    Xu, Jia
    Tin, Felicia
    Natarajan, Padmapriya
    Lee, Bee Lan
    Ong, Choon Nam
    Tint, Mya Thway
    Kee, Michelle Z. L.
    Muller-Riemenschneider, Falk
    Gluckman, Peter D.
    Meaney, Michael J.
    Kumar, Mukkesh
    Karnani, Neerja
    Eriksson, Johan G.
    Nandanan, Bindu
    Wyss, Adrian
    Cameron-Smith, David
    NUTRIENTS, 2023, 15 (10)
  • [24] Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial
    Pasqua, Melissa-Rosina
    Tsoukas, Michael A.
    Kobayati, Alessandra
    Aboznadah, Wedyan
    Jafar, Adnan
    Haidar, Ahmad
    NATURE MEDICINE, 2025, : 1239 - 1245
  • [25] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study
    Li, Haiyan
    Wei, Yudong
    Yang, Zhenhua
    Zhang, Shuang
    Xu, Xiuxiu
    Shuai, Mengmeng
    Vitse, Olivier
    Wu, Yiwen
    Baccara-Dinet, Marie T.
    Zhang, Yi
    Li, Jianyong
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2020, 20 (05) : 489 - 503
  • [26] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study
    Haiyan Li
    Yudong Wei
    Zhenhua Yang
    Shuang Zhang
    Xiuxiu Xu
    Mengmeng Shuai
    Olivier Vitse
    Yiwen Wu
    Marie T. Baccara-Dinet
    Yi Zhang
    Jianyong Li
    American Journal of Cardiovascular Drugs, 2020, 20 : 489 - 503
  • [27] SAFETY AND TOLERABILITY OF MICROBIAL INULINASE SUPPLEMENTATION IN HEALTHY ADULTS: A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Garvey, Sean M.
    LeMoire, Ashley
    Wang, Jun
    Lin, Lois
    Sharif, Bisma
    Bier, Anthony
    Baisley, Joshua
    Tinker, Kelly M.
    Boyd, Robert C.
    GASTROENTEROLOGY, 2024, 166 (05) : S876 - S876
  • [28] Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study
    Zhao, Xue
    Liu, Hongzhong
    Tian, Wei
    Fang, Ligang
    Yu, Mengyang
    Wu, Xiaofei
    Liu, Aijing
    Wan, Ruijie
    Li, Li
    Luo, Jinghui
    Li, Yuqiong
    Liu, Bo
    He, Yu
    Chen, Xiaowen
    Li, Yuan
    Xu, Donghong
    Wang, Hongyun
    Han, Xiaohong
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [29] A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants
    Li, Yunfei
    Zhang, Hua
    Pandya, Hitesh
    Miao, Liyan
    Reid, Fred
    Jimenez, Eulalia
    Sadiq, Muhammad Waqas
    Moate, Rachel
    Lei, Alejhandra
    Zhou, Xiao-Hong
    Kell, Chris
    Ding, Junjie
    Zhang, Guanlin
    Zhao, Lina
    Ge, Xiaoyun
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (06): : 665 - 671
  • [30] Safety, tolerability, and pharmacokinetics of HRS9432(A) injection in healthy Chinese subjects: a phase-I randomized, double-blind, dose escalation, placebo-controlled study
    Yan, Xin
    Huang, Yuanyuan
    Xie, Jinlian
    Wu, Qian
    Yang, Shuang
    Yang, Xiaoyan
    Chen, Honghui
    Huang, Jie
    Yang, Guoping
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (07) : e0052424
12345